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Abstract
Background: Delivering efficient and effective healthcare is crucial for a condition as burdensome as low back pain
(LBP). Stratified care strategies may be worthwhile, but rely on early and accurate patient screening using a valid
and reliable instrument. The purpose of this study was to evaluate the performance of LBP screening instruments
for determining risk of poor outcome in adults with LBP of less than 3 months duration.
Methods: Medline, Embase, CINAHL, PsycINFO, PEDro, Web of Science, SciVerse SCOPUS, and Cochrane Central Register
of Controlled Trials were searched from June 2014 to March 2016. Prospective cohort studies involving patients with
acute and subacute LBP were included. Studies administered a prognostic screening instrument at inception and
reported outcomes at least 12 weeks after screening. Two independent reviewers extracted relevant data using a
standardised spreadsheet. We defined poor outcome for pain to be≥ 3 on an 11-point numeric rating scale and poor
outcome for disability to be scores of≥ 30% disabled (on the study authors' chosen disability outcome measure).
Results: We identified 18 eligible studies investigating seven instruments. Five studies investigated the STarT Back Tool:
performance for discriminating pain outcomes at follow-up was ‘non-informative’ (pooled AUC = 0.59 (0.55–0.63), n =
1153) and ‘acceptable’ for discriminating disability outcomes (pooled AUC = 0.74 (0.66–0.82), n = 821). Seven studies
investigated the Orebro Musculoskeletal Pain Screening Questionnaire: performance was ‘poor’ for discriminating pain
outcomes (pooled AUC = 0.69 (0.62–0.76), n = 360), ‘acceptable’ for disability outcomes (pooled AUC = 0.75 (0.69–0.82),
n = 512), and ‘excellent’ for absenteeism outcomes (pooled AUC = 0.83 (0.75–0.90), n = 243). Two studies investigated
the Vermont Disability Prediction Questionnaire and four further instruments were investigated in single studies only.
Conclusions: LBP screening instruments administered in primary care perform poorly at assigning higher risk scores to
individuals who develop chronic pain than to those who do not. Risks of a poor disability outcome and prolonged
absenteeism are likely to be estimated with greater accuracy. It is important that clinicians who use screening tools to obtain
prognostic information consider the potential for misclassification of patient risk and its consequences for care decisions
based on screening. However, it needs to be acknowledged that the outcomes on which we evaluated these screening
instruments in some cases had a different threshold, outcome, and time period than those they were designed to predict.
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Background
A current trend in health service delivery towards the
provision of stratified models of care [1–3] offers potential
to optimise treatment benefits, reduce harms and maxi-
mise healthcare efficiency. Stratified approaches aim to
match patients to the most appropriate care pathways on
the basis of their presentation. A common approach bases
stratification on patients’ prognostic profile, which re-
quires early, accurate screening using a valid and reliable
instrument. By so doing, care decisions aim to offer treat-
ment to those who need it most and avoid over-treatment
of those who need it least.
Better matching of patients to care is particularly im-
portant for a condition as burdensome as low back pain
(LBP) [4, 5]. The prognosis of chronic LBP – when symp-
toms persist beyond 3 months – is poor [6]. This warrants
a focus on the potential for intervention to be appropri-
ately targeted prior to the development of chronic pain.
Improved understanding of factors associated with
chronic LBP [7–10] has led to the development of self-
report questionnaires containing multiple variables
known to have prognostic relevance. These prognostic
screening instruments (PSIs; also referred to as predict-
ive tools) assess certain characteristics of an individual’s
pain experience (including pain intensity and functional
impairment) and certain psychosocial factors (e.g. be-
liefs, catastrophisation, anxiety and depression). These
prognostic variables have been shown to be associated
with specific outcome measures and time frames [11].
PSIs are widely recommended to inform the manage-
ment of LBP [12–15], with updated international guide-
lines encouraging the use of risk stratification to guide
care decisions. A possible consequence of these broad
recommendations is that PSIs are likely to be used for
purposes other than the specific purpose for which they
were intended and in varied clinical settings. These fac-
tors may impact instrument performance, with implica-
tions for care decisions based on screening.
As the use of PSIs to inform care delivery becomes
more widely adopted, it is important to further consider
the uncertainty that surrounds their accuracy [16, 17].
We investigate how PSIs perform (individually and gen-
erally) when administered for the purpose of predicting
the likely course of LBP. The aim of this review was to
determine how well LBP PSIs discriminate between pa-
tients who develop a poor outcome and those who do
not in adults with LBP of less than 3 months duration.
Methods
This systematic review is reported in accordance with
the statement for Preferred Reporting Items for System-
atic Reviews and Meta-Analysis (PRISMA) [18] (see
Additional file 1).
Registration
Our protocol was registered a priori on the PROSPERO
International prospective register of systematic reviews
(http://www.crd.york.ac.uk/PROSPERO/display_record.asp?
ID=CRD42015015778)
Data sources and searches
Between June 23 and July 7, 2014, eight electronic da-
tabases (Medline (OvidSP), CINAHL (EBSCO host),
EMBASE (OvidSP), PsycINFO (OvidSP), PEDro,
Cochrane Central Register of Controlled Trials (CEN-
TRAL) (OvidSP), Web of Science (ISI) and SciVerse
SCOPUS) were systematically searched by a single re-
viewer to identify eligible studies. No time limits were
applied, but studies were limited to English language
publications and those involving human participants.
Search terms included the following keywords and
their variations: low back pain, sciatica, radiculopathy,
risk, screening, questionnaire, instrument, prediction,
prognosis, validity. While LBP was of principle inter-
est, studies were not excluded if they involved partici-
pants with leg pain/sciatica or radiculopathy
(conditions which involve a low-back disorder and are
usually accompanied by LBP). Table 1 shows the full
search strategy. The reference lists of all included ar-
ticles and relevant review articles were later searched
to identify any additional studies. Searching of all da-
tabases was updated on June 29 and December 22,
2015, and June 30, 2016.
Eligibility criteria
Types of participants
Studies were eligible if they involved adults (aged 18 or
over) with ‘recent onset’ LBP (i.e. acute LBP (0–6 weeks)
or subacute LBP (6 weeks to 3 months)), with or without
leg pain. Studies involving participants with recent-onset
and participants with chronic symptoms were included
with the intention of requesting from study authors the
data from the ‘recent onset’ participants only. Studies in-
cluding participants with pain in other body regions
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were considered eligible if more than 75% had LBP.
Cohorts of compensable and non-compensable patients
presenting to primary, secondary and tertiary care set-
tings were eligible for inclusion. It was also considered
appropriate to include individuals registered on workers
compensation databases, because it was assumed that
this occurs in conjunction with presentation to a health-
care provider. Participants may have presented with a
first episode of pain or report episodic/recurrent LBP,
provided that the current painful episode was immedi-
ately preceded by a minimum of one pain-free month as
suggested previously [19].
Types of studies
Prospective cohort studies meeting a Level I or Level II
quality standard according to the National Health and
Medical Research Council of Australia (NHMRC) evi-
dence hierarchy for prognostic studies [20] were in-
cluded. According to this standard, participants in these
studies must have been recruited as a consecutive series
of new presentations in any healthcare setting and been
subject to longitudinal assessment. Studies classified as
NHMRC Level III and IV evidence, including retrospect-
ive cohort studies, analysis of a single arm of a
randomised controlled trial or case series reports, were
excluded. Included studies involved the application of a
previously developed PSI within the first 3 months of an
episode of LBP and reported follow-up outcomes at a
minimum of 12 weeks from initial screening.
We defined a PSI as an instrument that met all of the
following criteria: (1) a self-report questionnaire; (2) as-
sesses multiple factors or constructs that have predictive
validity for patients with musculoskeletal pain; and (3)
was developed to provide prognostic information for
musculoskeletal conditions. The broad term of ‘muscu-
loskeletal’ pain rather than LBP was selected to define
the PSIs to avoid exclusion of instruments that had been
developed for use with musculoskeletal conditions and
subsequently validated for LBP cohorts. Studies were not
excluded on the basis of how the instrument was devel-
oped, or the primary intention of the instrument (as-
cribed by the developers). For example, the Keele STarT
Back Tool (SBT) was developed to include only ‘modifi-
able’ prognostic factors and was specifically intended for
the purpose of matching subgroups of patients to strati-
fied care pathways. Of primary importance to us was the
inclusion of all instruments currently being widely used
to offer prognostic information, or considered by the
wider community of clinicians and researchers to be
able to offer prognostic information. Included studies
were required to report associations between the PSI
scores and participant outcomes, and aimed, a priori, to
evaluate the instrument for its predictive validity. De-
velopment studies were excluded to avoid including
PSIs that had been insufficiently validated for clinical
application [21].
Types of outcomes
To be included, studies must have reported one or more
of the following outcomes:
1. Pain intensity as measured using a visual analogue
scale, numeric rating scale (NRS), verbal rating scale
or Likert scale
2. Disability as measured by validated self-report
questionnaires
3. Sick leave or days absent from work or return to
work status
4. Self-reported recovery using a global perceived effect
scale or a Likert (recovery) scale
Study selection
Following removal of duplicate articles, two reviewers
independently assessed the titles and abstracts of studies
identified by the search for eligibility. AW assessed all
the articles; EK and LG each assessed 50% of the articles.
All reviewers applied a checklist of inclusion and exclu-
sion criteria. Disagreements were discussed. The full
Table 1 Search Strategy Example. The search strategy below
was used to conduct the MEDLINE search for the current




2 Low Back Pain/
3 Sciatica/
4 Radiculopathy/
5 (back pain or low back pain or radiculopathy or sciatica or
back?ache or lumbago).mpa
6 (pain or ache or aching or complaint or dysfunction or disability
or disorder).mpa
7 Back or spine or lumbar or lumbar spine or low*back).mpa
8 6 and 7
9 1 or 2 or 3 or 4 or 5 or 8
10 (screen* or risk screen* or risk).mpa
11 (tool or questionnaire or instrument).mpa
12 10 and 11
13 9 and 12
14 (predict* or prognosis or prediction rule* or early identification or
predictive validity or predictive factors or prognostic or prognostic
indicators).mpa
15 13 and 14
16 Limit 15 to (English language and humans)
amp: title, abstract, original title, name of substance word, subject heading
word, keyword heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier
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paper was obtained for further assessment if necessary.
Full texts of studies potentially fulfilling the eligibility
criteria were retrieved, with subsequent independent
assessment of all articles undertaken by EK and LG.
Reasons for study exclusion were noted on a checklist
with any disagreements resolved by discussion.
Data extraction and analysis
EK and either LG or LR independently reviewed the full
text of eligible studies and extracted relevant data using
a standardised spreadsheet. Extracted data included de-
tails of the healthcare setting, recruitment, study popula-
tion, number of participants, loss to follow-up, symptom
duration, LBP history, compensability, concomitant
treatments, outcome measurement, statistical analyses,
and reporting quality. Discrepancies in extracted data
were identified and checked. If the required data could
not be extracted, authors were emailed with the specific
enquiry. If no response was received, authors were re-
emailed after 2 weeks, and (finally) after a further week.
Predictive validity is conventionally assessed using re-
ceiver operating characteristic (ROC) curve analysis,
with area under the curve (AUC) statistic being the most
routinely reported measure of performance [22]. AUC
values provide an overall measure of the discriminative
ability of the instrument. Values range from 0.5 to 1.0,
where 0.5 indicates that the instrument is no better than
chance at discriminating those participants who will
have a poor outcome, from those who will recover. AUC
values of < 0.6 suggest that the instrument or screening
test should be regarded as ‘uninformative’; 0.6–0.7 indi-
cates ‘poor’ discrimination; 0.7–0.8 ‘acceptable’; 0.8–0.9
‘excellent’; and above 0.9 ‘outstanding’ [23, 24].
Where possible, we extracted AUC values with 95%
confidence intervals to enable analysis and comparison
of the PSIs. When AUC values were not provided, study
authors were requested to either (1) calculate AUC
values for the recent-onset participants or (2) provide
primary data to allow calculation of AUC values. If the
authors chose to calculate AUC values, we offered fur-
ther instruction on how to do so. The primary outcome
of this study was pain intensity at follow-up; poor out-
come was pain ≥ 3 on an 11-point NRS, which was based
on Grotle et al. [25] and Traeger et al. [26], and follows
evidence that many people with scores of < 3 consider
themselves to be recovered [27]. All study authors who
reported obtaining pain NRS scores were requested to
dichotomise pain outcomes according to this definition.
Authors then re-analysed their results or offered out-
come data and baseline screening scores to enable us to
undertake ROC analysis. When authors were willing to
assist with dichotomising disability outcomes, scores
of ≥ 30% disabled (on their chosen disability outcome
measure) were classified as ‘poor outcome’. A similar
approach to revision of the ROC analyses was under-
taken. No attempt was made to request re-definition of
sick leave and recovery outcomes (secondary outcomes
of this study).
Meta-analysis was planned considering the potential to
pool data according to (1) individual PSIs and (2) spe-
cific outcomes. For data pooling to be appropriate, it
was considered important that (1) outcome measures
were defined consistently, (2) the clinical settings were
similar (e.g. all primary care), and (3) uniform statistical
analyses had been applied. Interpretation of random ef-
fects models was planned due to assumed variability in
participant cohorts. Meta-analyses, including tests for
statistical heterogeneity (using I2 test) were undertaken
using MedCalc Statistical Software (version 14.12.0). A
post-hoc sensitivity analysis was undertaken to explore
the influence of study variation in classification of poor
disability outcomes on the meta-analysis.
Assessment of methodological quality
EK and either LG or LR independently undertook the
risk of bias (ROB) assessment using the Quality in
Prognostic Studies (QUIPS) tool [28]. This tool was de-
veloped specifically for assessing bias in studies of prog-
nostic factors. Items across six domains (study
participation, study attrition, prognostic factor meas-
urement, outcome measurement, study confounding,
and statistical analysis and reporting) were considered
individually for each study. A guideline was used to
classify each item as ‘high’, ‘moderate’ or ‘low’ risk of
bias. If insufficient information was available to assess
potential bias, that domain was rated ‘unclear’. An
overall ROB was established for each individual study
according to Bruls et al. [29]. The overall ROB for a
study was rated as ‘low’ (indicating a high quality study)
when all or most (4–6) of the six bias domains were
fulfilled, with each domain rated as ‘low’ or ‘moderate’.
The overall ROB was rated as ‘high’ (indicating a low
quality study) when one or more of the six bias do-
mains were rated as ‘high’ or ‘unclear’. Disagreements
in ratings were discussed and, if not resolved, a third
reviewer (SH) was consulted. Studies rated as having a




Our initial search identified 1557 studies for potential
inclusion, from which 110 full text articles were
retrieved. Twenty-one studies satisfied all criteria for
inclusion. Three further studies were identified
through repeat searching. The authors of 13 studies
were contacted to request data pertaining specifically
to the recent onset participants. Unsuccessful
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attempts to obtain these data meant that six studies
were excluded [30–35]. Eighteen studies were finally
included in this review.
Details of studies accepted and rejected during the se-
lection process are illustrated in Fig. 1. Table 2 details
the studies that were excluded based on the participants’
pain duration at baseline screening. Key study character-
istics and results are summarised in Table 3 (at the end
of the manuscript).
Study characteristics
Included studies were conducted between 1996 and
2015, in 10 different countries – USA (n = 5), UK (n = 3),
Australia (n = 2), Netherlands (n = 2), and one in each of
Norway, Denmark, China, Belgium, Germany, and
Canada (Table 3). Seventeen studies included in this re-
view were undertaken in primary healthcare settings,
defined, according to the World Health Organization
Declaration of Alma-Ata (1978), as involving the indi-
vidual’s “first level of contact” with “promotive, pre-
ventive, curative and rehabilitative services” ([36] p.
2). One investigation [37] was conducted in a Hospital
outpatient physiotherapy setting, considered ‘secondary
care’. Five studies included ‘working adult’ populations; 13
studies included ‘general adult’ participants (some of
whom were employed). Of those 13 studies, three were
undertaken in Physiotherapy settings, four in Chiroprac-
tic clinics, six in General Practice settings, two in a
Hospital emergency/Outpatient department and two
in combinations of these healthcare settings.
PSIs
Seven instruments satisfied our criteria for classifica-
tion as a PSI: the SBT (five studies), the Orebro Mus-
culoskeletal Pain Screening Questionnaire (OMPSQ;
seven studies), the Vermont Disability Prediction
Questionnaire (VDPQ; two studies), the Back
Disability Risk Questionnaire (BDRQ; one study), the
Absenteeism Screening Questionnaire (ASQ; one
study), the Chronic Pain Risk Score (CPRS; one study),
and the Hancock Clinical Prediction Rule (HCPR; one
study). The PSIs are summarised in Table 4.
Outcomes
Six studies assessed pain intensity (using a NRS) as a pri-
mary outcome and a further eight studies assessed pain as
a secondary outcome. Measures of work absenteeism or
self-reported recovery ratings were reported as primary
outcomes in four studies each. Disability was assessed
as a primary outcome in five studies and as a secondary
outcome in a further five studies. Definitions of ‘poor
outcome’ (after an episode of LBP) were highly variable.
For studies identifying pain as the primary outcome,
poor outcome was variably defined as NRS scores of > 0
[38], > 1 [39], > 2 [25], and > 4 [40]; one study [41] de-
fined sustained recovery from LBP by NRS scores of 0




Discrimination of pain outcomes The five studies [38,
43–46] investigating the SBT used pain as an outcome
measure. All authors provided raw data for statistical
analysis or followed guidance for analysis of their recent
onset data. Consistent classification of ‘poor outcome’
allowed pooling of AUC values (pooled AUC = 0.59
(0.55–0.63); Table 5). Discriminative performance was
‘non-informative’. There was no evidence of statistical
heterogeneity (I2 = 0.00%, P = 0.47).
Discrimination of disability outcomes Three SBT
studies [38, 43, 46] included disability as an outcome
measure. ‘Poor outcome’ (in disability terms) was
Fig. 1 Flow diagram of study selection. LBP low back pain, PSI prognostic screening instrument
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defined consistently. The pooled AUC value of 0.74
(0.66–0.82) indicated ‘acceptable’ [23, 24] discrimin-
ation. There was substantial statistical heterogeneity
(I2 = 80.95%, P = 0.005). To explore the source of het-
erogeneity, two studies [38, 46] that did not have over-
lapping confidence intervals were separately removed.
Heterogeneity was no longer significant in both ana-
lyses (P > 0.05), with impact on the AUC values
(Table 6).
OMPSQ
Discrimination of pain outcomes Four of the seven
studies [25, 39, 42, 47] investigating the OMPSQ in-
cluded pain as an outcome measure. Consistent classifi-
cation of ‘poor outcome’ was achieved, allowing pooling
of all AUC values (pooled AUC = 0.69 (0.62–0.76);
Table 5). Discriminative performance was ‘poor’. Statis-
tical heterogeneity was moderate but not statistically sig-
nificant (I2 = 40.95%, P = 0.17).
Discrimination of disability outcomes Five OMPSQ
studies included disability as an outcome measure.
Three studies classified ‘poor outcome’ as ≥ 30% disabil-
ity [39, 42, 47], one used ≥ 20% [25] and one used ≥ 40%
[48]. Despite different definitions, the results were
pooled and post-hoc sensitivity analysis confirmed this
to be acceptable (Table 7). Discriminative performance
was ‘acceptable’ [23, 24] (pooled AUC = 0.75 (0.69–
0.82)). There was no evidence of statistical heterogeneity
(I2 = 0.00%, P = 0.64).
Discrimination of absenteeism outcomes The
OMPSQ offers ‘excellent’ discrimination of prolonged
absenteeism at 6 months (pooled AUC from three stud-
ies [25, 39, 42] = 0.83 (0.75–0.90); and ‘acceptable’ dis-
crimination of prolonged absenteeism at 12 months
(pooled AUC from two studies [25, 37] = 0.71 (0.64–
0.78). There was no statistical heterogeneity (I2 = 0.00%,
P = 0.86).
All instruments
Discrimination of pain outcomes Twelve investigations
in primary care settings (using five different PSIs) re-
ported pain outcomes at medium term follow-up. Poor
outcome was consistently defined as NRS scores ≥ 3.
Data were pooled for studies using the SBT and
OMPSQ. Meta-analysis enabled visual comparison of
the discriminative performances of all instruments
(Fig. 2). The pooled performance was ‘poor’ (pooled
AUC = 0.63 (0.60–0.65)). The I2 of 51.16% may represent
moderate statistical heterogeneity (P = 0.08).
Discrimination of disability outcomes Nine studies
(involving three PSIs) reported disability outcomes at
medium term follow-up. Poor outcome was consistently
defined as ≥ 30% disabled, with the exception of two of
the OMPSQ studies as noted previously (Grotle et al.
[25] ≥ 20% and Schmidt et al. [48] ≥ 40%).
Data were pooled for studies using the SBT and the
OMPSQ. Meta-analysis enabled visual comparison of
the discriminative performances of all instruments
(Fig. 3). The pooled performance was ‘acceptable’
(pooled AUC = 0.71 (0.66–0.76)) and indicated sub-
stantial heterogeneity (I2 = 69.89%, P = 0.04). Graphical
representation suggests that the SBT and the OMPSQ
out-performed the BDRQ. Heterogeneity was resolved
Table 2 Studies excluded based on participants pain duration at baseline screening
Reference Prognostic screening instruments Reason for exclusion
Bergstrom et al. (2011) [62] MPI-S Mixed cohort;b authors did not differentiate an acute/subacute group
Bernstein et al. (1994) [63] SCL-90-R Chronic pain cohort (pain > 3 months)
Morso et al. (2011) [64] PainDETECT questionnaire Chronic pain cohort (pain duration 3–12 months)
Late exclusions:a
Fischer et al. (2014) [30] HKF-R10 Mixed cohort;b authors did not differentiate an acute/subacute group
Hurley et al. (2001) [31] ALBPSQ Mixed cohortb,c
Linton et al. (2011) [32] OMPSQ (Short Form) Mixed cohortb,c
Morso et al. (2013) [65] SBT Mixed cohortb,c
Morso et al. (2014) [33] SBT Mixed cohortb,c
Cats-Baril et al. (1991) [35] VDPQ Mixed cohort;b unable to contact authors to request data from
recent onset participants
aStudy authors were contacted (or contact attempts were made) prior to study exclusion
bCombination of acute/subacute/chronic pain participants
cAuthors unable to provide data for ‘recent-onset’ participants
MPI-S Multidimensional Pain Inventory (Swedish version), SCL-90-R Symptom Checklist 90 Revised, HKF-R10 Heidelberg Short Early Risk Assessment Questionnaire,
ALBPSQ Acute Low Back Pain Screening Questionnaire, OMPSQ Orebro Musculoskeletal Pain Screening Questionnaire, SBT STarT Back Screening Tool, VDPQ
Vermont Disability Prediction Questionnaire
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Table 3 Key study characteristics and results
Reference Country of investigation
and clinical setting











aPain NRS score≥ 3
aDisability (ODI score ≥ 30%)







aPain NRS score≥ 3
477 (151, 31.7%) aPain 0.597 (0.499–0.694)





RMDQ score ≥ 7
aPain NRS score≥ 3
aDisability ≥ 30% RMDQ
177 at follow-up.









aPain NRS score≥ 3
aDisability ≥ 30% RMDQ







aPain NRS score≥ 3
284 (192, 67.6%) aPain 0.59 (0.48–0.69)






Functional status ≥ 10%
Problem severity > 1
Absenteeism > 0 days
Long term absenteeism
> 28 days
aPain NRS score≥ 3
aDisability (SFI score ≥ 30%)
66 (58, 87.9%)
(OMPSQ -Original)
Functional status 0.88 (0.78–0.99)











(27% recruited through advertisement)
At 6 & 12 months:
Pain NRS score ≥ 3
Disability (RMDQ score > 4)
Sick leave (> 30 days)
123 (112, 91.1%) Pain 0.62 (0.51–0.73)
Disability 0.68 (0.56–0.80)





Not recovered at 12 weeks
aPain NRS score≥ 3
aDisability QBPDS ≥ 30%)







12 months: score of ‘slightly
improved’ or worse at two
or more follow-up time points
314 (296, 94.3%) Non-recovery 0.61 (0.54–0.67)
Law et al. 2013
[37]
China
Physiotherapy clinics in public
hospitals
12 months post discharge:
Failure to return to work
Prolonged sick leave (> 30 days)
241 (220, 91.3%) Return to work 0.69 (0.62–0.76)




Emergency facility or outpatient clinic
At 6 months:
Pain index score > 16
ODI ≥ 20%
Functional index < 45
Work absence > 30 days
aPain NRS score≥ 3
aDisability ≥ 30% ODI


















to three GCPS disability items)
181 (112, 62%) Disability (OMPSQ scale sum score)
0.79 (0.67–0.90)
Disability (OMPSQ item sum score)
0.77 (0.66–0.87)




Vermont Department of Labour
and Industry database
Not returned to work at 3 months 166 (163, 98%) Return to work 0.92





Vermont Department of Labour
and Industry database
Not returned to work at 3 months 304 (268, 88.2%) Return to work 0.78
(no confidence interval or
standard error reported)
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with removal of the BDRQ study: pooled AUC = 0.75
(0.70–0.80, I2 = 0.00%, P = 0.98).
Discrimination of absenteeism outcomes Variability in
follow-up time-points and outcome measures used in
studies with absenteeism outcomes [25, 39, 40, 42, 49–
51] did not allow comparisons to be made between
instruments.
Studies not included in the meta-analysis
The following four of studies were not included in a
quantitative meta-analysis since they used outcome mea-
sures dissimilar to the measures used in the other in-
cluded studies.
Jellema et al. 2007 [52] – OMPSQ
This study investigated the use of the OMPSQ in a gen-
eral adult population for prediction of non-recovery at
12 months post-screening (defined as a score of slightly
improved or worse on a 7-point Likert scale, at two or
more follow-up time points). ‘Good’ instrument calibra-
tion was reported (i.e. agreement between predicted and
observed risks); however, discriminative ability for pre-
dicting long-term global recovery was poor (AUC = 0.61
(0.54–0.67).
Hazard et al. 1996 [49] & 1997 [50] – VDPQ
These studies of prognostic screening indicated the poten-
tial utility of the VDPQ to predict return to work at
3 months post low back injury. The initial validation study
[49] revealed ‘outstanding’ discriminative performance
(AUC= 0.92, no confidence intervals obtained) and the
subsequent study [50] suggested it was ‘acceptable’ (AUC
= 0.78; no confidence intervals obtained).
Truchon et al. (2012) [51] – ASQ
This study suggested ‘acceptable’ discrimination of long-
term absenteeism (>182 cumulative days) at 12-month
follow-up using the ASQ (AUC = 0.73; no confidence in-
tervals obtained).
Methodologic quality
Sixteen of the 18 included studies were assessed to
have a low risk of bias and were thereby regarded to
be of high quality. Two studies were regarded to have
a high risk of bias primarily due to a high rate of loss
to follow-up (> 40%). The assessment of individual
study quality is reported in Table 8 (at the end of the
manuscript).
Discussion
Based on high quality prognostic studies, this system-
atic review provides evidence that LBP PSIs perform
poorly at assigning higher risk scores to individuals
who develop chronic pain, than to those who do not.
Clinicians can expect that a PSI, administered within
the first 3 months of an episode of LBP will correctly
classify a patient as high or low risk of developing
chronic pain between 60% and 70% of the time. PSIs
perform somewhat better at discriminating between
patients who will and will not have persisting disabil-
ity (70–80% probability of correct classification) and
appear most successful (> 80% probability) at








Absenteeism > 182 cumulative days
535 (310, 58%) Absenteeism 0.73
(no confidence intervals or
standard error reported)






Pain grades 3 & 4
aPain NRS ≥ 3
458 (425, 92.8%) Pain grades 3 & 4 0.67 (0.59–0.72)
aPain 0.67 (0.59–0.72)








aPain NRS score≥ 3
aDisability ≥ 30% RMDQ
568 (519, 91.4%) aPain 0.61 (0.56–0.66)
aDisability 0.66 (0.62–0.70)









(0 or 1/10 on a NRS for 7 consecutive days)
aPain NRS ≥ 3
956 (937, 82%) Sustained recovery 0.60
(0.56–0.64)
aPain 0.62 (0.60–0.65)
aUnpublished data for ‘recent onset’ participants, provided on request
NRS numeric rating scale, ODI Oswestry Disability Index, RMDQ Roland Morris Disability Questionnaire, SFI Spine Functional Index, QBPDS Quebec Back Pain
Disability Scale, GCPS Graded Chronic Pain Scale, OMPSQ Orebro Musculoskeletal Pain Screening Questionnaire
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discriminating between patients who will or will not
return to work successfully.
This review also informs about the prognostic per-
formance of specific instruments. The OMPSQ and
VDPQ appear to perform well at predicting return to
work outcomes and the SBT and the OMPSQ have
modest predictive value for disability outcomes, but
the included instruments demonstrate little value for
informing about likely pain outcomes. Problems
associated with using a screening instrument for a
purpose other than intended (i.e. based on interest in
a specifically defined outcome, at a specific time
point) have been introduced in this paper. The instru-
ments included in this study were designed to predict
outcomes at time points varying between 3 and
6 months. Two were designed to predict work absen-
teeism (VDPQ, ASQ), one to predict status on a
chronic pain scale (CPRS), one to predict LBP
Table 4 Summary of included predictive screening instruments
Instrument Summary of instrument Scoring method Cut-off scores/subgrouping
STarT Back Tool (SBT) [46] 9-item, self-report questionnaire; items
screen for predictors of persistent disabling
back pain and include radiating leg pain,
pain elsewhere, disability (2 items), fear,
anxiety, pessimistic patient expectations,
low mood and how much the patient is
bothered by their pain; all 9-items use a
response format of ‘agree’ or ‘disagree’,
with exception to the bothersomeness
item, which uses a Likert scale.
Two scores are produced – an
overall score and a distress
(psychosocial) subscale
Total scores of 3 or less
= low risk
If total score is 4 or more:
- Those with psychosocial
subscale scores of 3 or less
=medium risk
- Those with psychosocial
subscale scores of 4 or more
= high risk
Orebro Musculoskeletal Pain Screening
Questionnaire (OMPSQ) [67] and Acute
Low Back Pain Screening Questionnaire
(ALBPSQ) [68]
25-item, self-report questionnaires; items
screen for six factors: self-perceived function,
pain experience, fear-avoidance beliefs,
distress, return to work expectancy, and
pain coping
Total score calculated from 21
items and can range from 2
to 210 points; higher values
indicate more psychosocial
problems
A cut-off of 105 proposed for
indicating those ‘at risk’ of
persisting problems
OMPSQ (Short form) [32] 10-item questionnaire covering five
domains: self-perceived function, pain
experience, fear-avoidance beliefs,
distress, and return to work expectancy;
demonstrated to have similar discriminative
ability to original OMPSQ
Scores range from 0 to 100
(higher scores indicate
higher risk)
A cut-off of 50 recommended
to indicate those ‘at risk’ of
persisting pain related disability
Vermont Disability Prediction
Questionnaire (VDPQ) [49]
11-item self-report questionnaire; assesses
perceptions of who was to blame for the
injury, relationships with co-workers and
employer, confidence that they will
be working in 6 months, current work
status, job demands, availability of job
modifications, length of time employed,
and job satisfaction
Hand scored
(maximum score of 23)
No optimal cut-off
recommended
Back Disability Risk Questionnaire
(BDRQ) [40]
16-item self-report questionnaire; items
include demographics, health ratings,
workplace concerns, pain severity, mood,
and expectations for recovery




16-item, self-report questionnaire; assesses
potential occupational back pain disability
and risk factors including: work factors (3),
physical health (2), supervisor response (1),
pain (2), mood (2), wellness/job satisfaction
(3), and expectations for recovery (1); mixture
of nominal, ordinal and interval scale
response options
‘Flag’ related items are
summed and level of risk
categorised as low,
medium or high
0–1 flag items = low risk
2–3 items =medium risk
4–9 items = high risk
Chronic Pain Risk Score (CPRS) [61] Three graded chronic pain scale ratings
of pain intensity, three ratings of activity
interference, the number of activity
limitation days, the number of days with
pain in the past 6 months, depressive
symptoms, the number of painful sites





Hancock Clinical Prediction Rule
(HCPR) [69]
3-item self-report questionnaire, items
assess baseline pain (≤ 7/10), pain duration
(≤ 5 days) and number of previous painful
episodes (≤ 1)
Status on the prediction
rule determined by calculating
the number of predictors of
recovery present
Risk classification based on
the number of predictors
of recovery present (0–3)
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recovery (HCPR), and one to predict functional limi-
tation (SBT). Only two instruments (BDRQ, OMPSQ)
were developed to predict more than one clinical out-
come. This may have played a role in the poor per-
formance of several of the instruments when
evaluated according to the uniform methods we
employed.
While our classification of the SBT as a PSI may be ar-
guable, we considered that its clinical use as a prognostic
instrument warranted its inclusion in this review. The
NICE guidelines [15] recommend that clinicians use
tools such as the SBT to identify patients at risk of poor
outcome and tailor their management accordingly. Our
findings suggest, however, that there is need for caution
if the SBT is administered only for the purpose of pre-
dicting the risk of poor outcome. As a ‘stratified care
tool’ with matched treatment pathways, the merits of
the SBT have been reported elsewhere [2, 53].
While it is ideal that stratified care tools such as the
SBT have high predictive validity this may not be realis-
tic if the approach is to only include modifiable items
during instrument development. Additionally, screening
instruments designed for clinical use must be brief and
simple to score. A trade-off of these factors may be re-
duced discriminative performance. It can be noted that
the discriminative performance of the SBT is better in a
UK General Practice setting than in Physiotherapy or
Chiropractic settings – a finding consistent with the un-
derstanding that the usefulness of a screening instru-
ment is highly setting-specific [44, 54] and optimal in
the cohort for which it was developed [55]. In contrast,
however, the ‘excellent’ performance of the OMPSQ for
discriminating workers at risk of prolonged absenteeism
regardless of country and across varied clinical settings
suggests the wider utility of this PSI.
This study was prospectively registered with full ad-
herence to the published protocol. We used the QUIPS
methodological appraisal tool [28], a valid and reliable
tool for evaluating prognostic studies. The general qual-
ity of included studies was assessed to be high with the
exception of two studies that had high loss to follow-up
[44, 51]. To our knowledge, this is the first quantitative
synthesis and analysis of the discriminative performance
of PSIs. All previous systematic reviews of PSIs have
been unable to conduct meta-analyses of predictive ac-
curacy because of clinical heterogeneity [9, 17, 56, 57]. It
is also the first review to include studies testing the SBT.
Additional data obtained from study authors facilitated
data pooling from similar adult populations, with con-
sistent follow-up time points and identical classifications
of poor outcome. Pooling data from instruments that
were designed with different purposes in mind may,
however, limit the strength of the conclusions that can
be drawn from this study.
ROC analyses are recommended for discriminative ac-
curacy studies [58], but come with some limitations. A
ROC analysis requires dichotomisation of outcomes,
which means that the definition of ‘poor outcome’ can
affect findings. In the absence of a general consensus on
the definition of ‘poor outcome’, we followed previous
studies and recommendations [24, 27, 59]. The selected
cut-off score of ≥ 3/10 on a pain NRS was based on the
understanding that many people with pain scores of < 3
consider themselves to be ‘recovered’ [1]. Boonstra et al.
[60] support that people with pain NRS scores of ≤ 3
describe themselves to be experiencing only ‘mild’




All studies included 0.74 0.66–0.82 80.85% (0.01)
Hill et al. (2008) [46]
removed
0.68 0.63–0.73 0.00% (0.37)
Kongsted et al. (2015) [38] removed 0.80 0.74–0.86 0.00% (0.42)
AUC Area Under the Curve
Table 5 Meta-analyses: pooled data specific to predictive screening instrument and outcome measures
PSI Outcome Studies (Total N) Heterogeneity I2 (P) Pooled AUC value 95% confidence interval
SBT Pain (≥ 3) 5 studies (1153) 0.00% (0.47) 0.59 0.55–0.63
SBT Disability (≥ 30%) 3 studies (821) 80.95% (0.01) 0.74 0.66–0.82
OMPSQ Pain (≥ 3) 4 studies (360) 40.95% (0.17) 0.69 0.62–0.76
OMPSQ Disability (≥ 30%) 3 studies (512) 0.00% (0.42) 0.75 0.69–0.82
OMPSQ 6 month absenteeism (> 28 days) 3 studies (243) 0.00% (0.86) 0.83 0.75–0.90
OMPSQ 12 month absenteeism (> 30 days) 2 studies (440) 0.00% (0.90) 0.71 0.64–0.78
AUC Area Under the Curve, SBT STarT Back Tool, OMPSQ Orebro Musculoskeletal Pain Screening Questionnaire
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symptoms. We classified participants who were ‘not re-
covered’ at follow-up (or those experiencing more than
mild symptoms) as having a ‘poor outcome’. Since the
outcome classification can influence discriminative per-
formance, it would have been interesting to evaluate al-
ternative cut-off points for poor outcome for each of the
outcomes considered; this could be considered in further
research. The definitions we applied were used by sev-
eral included studies [25, 39, 42, 61]. In addition, AUC
values (derived from the ROC analysis) are a function of
sensitivity and specificity – both of which are influenced
by cohort characteristics (e.g. symptom severity and
psychological profile). Variations are therefore expected
for the same instrument among different populations.
Recommendations for the management of LBP in
primary care frequently include using available screen-
ing instruments to obtain information about ‘risk’ of
a poor outcome. This review highlights that clinicians
may need be cautious about placing too much weight
on PSIs during their clinical assessment, under the
misimpression that they are able to accurately
determine chronic pain risk. Using PSIs to allocate
care carries the risk that patients misclassified by PSIs
as low-risk are undertreated and patients misclassified
as high-risk are overtreated. Estimation of risk of poor dis-
ability outcomes and prolonged absenteeism are likely to
be more accurate – indicating that it is necessary to con-
sider the clinical outcomes of interest when seeking prog-
nostic information.
It is important to note, however, that this study inves-
tigated the predictive performance of PSIs and does not
inform whether the implementation of prognostic
screening improves outcomes for adults with recent
onset LBP. Alternative research approaches, namely ran-
domised ‘impact’ trials [1], are required to address this
question. Furthermore, it is relevant to consider whether
the use of PSIs offers more accurate estimation of a pa-
tient’s course of LBP than clinician judgement. Previous
studies comparing the discriminative performance of
screening instruments (including the SBT and the
OMPSQ) with primary care clinicians’ estimation of risk
of poor outcome [52, 38] have failed to show superior
capabilities of the questionnaires.
As highlighted in the PROGRESS recommendations
[21], the validation of predictive models requires a suc-
cession of steps from development through to external
validation and impact analysis – a process which has
been only partially fulfilled by the PSIs in this review.
Further research according to PROGRESS recommen-
dations will allow improved confidence in the selection
and application of available instruments. Less under-
stood factors (e.g. structural pathology, sleep or social
factors) should be further investigated and integrated
into prognostic models to improve predictive accuracy
beyond what is currently achievable. In addition, there
remains a need to undertake further prospective
Table 7 Post-hoc sensitivity analysis to explore the effect of
poor outcome classification on the discriminative performance




All studies included 0.75 0.69–0.82 0.00% (0.64)
Schmidt et al. (2016) [48]
removed (≥ 40%)
0.73 0.65–0.81 0.00% (0.60)
Grotle et al. (2006) [25]
removed (≥ 20%)
0.75 0.69–0.82 0.00% (0.50)
Schmidt et al. (2016) [48]
and Grotle et al. (2006)
removed [25]
0.74 0.65–0.82 0.00% (0.42)
AUC Area Under the Curve
Fig. 2 Meta-analysis of the discriminative performance of all instruments (for pain). SBT STarT Back Tool, OMPSQ Orebro Musculoskeletal Pain
Screening Questionnaire, BDRQ Back Disability Risk Quesionnaire, CPRS Chronic Pain Risk Score, HCPR Hancock Clinical Prediction Rule,
ROC Receiver Operating Characteristic
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clinical trials investigating the effectiveness of screen-
ing to direct stratified care approaches for patients
with LBP. The performance of a stratified care instru-
ment is best evaluated by an effect size derived from a
randomised controlled trial.
Conclusions
LBP screening instruments administered in primary care
perform poorly at assigning higher risk scores to
individuals who develop chronic pain, than to those who
do not develop chronic pain. Risks of a poor disability out-
come and prolonged absenteeism are likely to be esti-
mated with greater accuracy. While PSIs may have useful
clinical application, it is important that clinicians who use
screening tools to obtain prognostic information consider
the potential for misclassification of patient risk and its
consequences for care decisions based on screening. How-
ever, it needs to be acknowledged that the outcomes on
Fig. 3 Meta-analysis of the discriminative performance of all instruments (for disability). SBT STarT Back Tool, OMPSQ Orebro Musculoskeletal Pain
Screening Questionnaire, BDRQ Back Disability Risk Quesionnaire, ROC Receiver Operating Characteristic














of risk of biasa
Beneciuk et al. 2012 [43] Low Moderate Moderate Low Low Low Low
Field & Newell 2012 [44] Moderate Moderate Low Low Low Low Low
Gabel et al. 2011 [39] Moderate Low Moderate Low Low Low Low
Grotle et al. 2006 [25] Moderate Low Moderate Low Low Moderate Low
Hazard et al. 1996 [49] Moderate Low Low Low Low Moderate Low
Hazard et al. 1997 [50] Moderate Low Low Low Low Low Low
Heneweer et al. 2007 [66] Moderate Low Low Low Low Low Low
Hill et al. 2008 [46] Moderate Moderate Low Low Low Low Low
Jellema et al. 2007 [52] Low Low Low Moderate Low Low Low
Kongsted et al. 2015 [38] Low Low Low Low Low Low Low
Law et al. 2013 [37] Low Moderate Low Low Moderate Low Low
Newell et al. 2014 [45] Low High Moderate Low Low Low High
Nonclercq et al. 2010 [42] Moderate Low Low Low Low Low Low
Shaw et al. 2009 [40] Low Low Low Low Low Low Low
Schmidt et al. 2016 [48] Moderate Moderate Low Low Low Low Low
Truchon et al. 2012 [51] Moderate High Low Moderate Low Moderate High
Turner et al. 2013 [61] Moderate Low Low Low Low Low Low
Williams et al. 2014 [41] Low Low Low Low Low Low Low
aThe overall assessment of risk of bias for a study was rated as ‘low’ when all or most (4–6) of the six bias domains were fulfilled, with each domain rated as ‘low’
or ‘moderate’. The overall risk of bias was rated as ‘high’ when one or more of the six bias domains were rated as ‘high’ or ‘unclear’. Studies with low overall risk
of bias were considered high quality
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which we evaluated these screening instruments in some
cases had a different threshold, outcome and time period
than those they were designed to predict.
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